Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by SageView Advisory Group LLC

SageView Advisory Group LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,532 shares of the medical research company’s stock after buying an additional 359 shares during the quarter. SageView Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $2,003,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TMO. Kestra Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 15.7% during the 3rd quarter. Kestra Advisory Services LLC now owns 27,014 shares of the medical research company’s stock worth $13,674,000 after purchasing an additional 3,666 shares during the period. QRG Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $12,894,000. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $18,442,000. Envestnet Asset Management Inc. raised its position in shares of Thermo Fisher Scientific by 21.9% in the 3rd quarter. Envestnet Asset Management Inc. now owns 698,445 shares of the medical research company’s stock worth $353,532,000 after buying an additional 125,267 shares during the period. Finally, TRUE Private Wealth Advisors raised its position in shares of Thermo Fisher Scientific by 10.3% in the 3rd quarter. TRUE Private Wealth Advisors now owns 1,202 shares of the medical research company’s stock worth $608,000 after buying an additional 112 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,000 shares of company stock valued at $12,532,780. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.7 %

NYSE:TMO opened at $568.00 on Tuesday. The company has a market capitalization of $216.82 billion, a price-to-earnings ratio of 36.43, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The stock has a 50-day simple moving average of $574.95 and a 200 day simple moving average of $559.33. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

TMO has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Robert W. Baird cut their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, Evercore ISI increased their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $607.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.